Licorice Compound Gancaonin N Blocks Fat Cell Formation in Landmark Study

A prenylated isoflavone extracted from licorice root, a plant long revered in Asian herbal medicine, has emerged as a surprising candidate in the fight against obesity. In a new study published in BMC Complementary Medicine and Therapies, researchers from Kyung Hee University and collaborating Korean institutions report that gancaonin N, a bioactive compound derived from Glycyrrhiza uralensis, significantly suppresses the formation of fat cells and the accumulation of lipids in a well-established cellular model of adipogenesis. The findings, which combine computational network pharmacology with rigorous laboratory validation, offer a molecular window into how a traditional medicinal plant might influence one of the most pressing metabolic health challenges of our time.

Obesity arises from a complex interplay of genetic predisposition, environmental pressures, and lifestyle factors, culminating in the abnormal accumulation of adipose tissue. At the cellular level, the expansion of fat mass depends on adipogenesis, the process by which precursor cells differentiate into mature adipocytes that store lipid. Interrupting this process has long been a strategic goal for metabolic research, and natural products have increasingly been scrutinized as sources of candidate anti-adipogenic molecules. Glycyrrhiza uralensis, known in traditional medicine for its anti-inflammatory and antioxidant properties, had previously been linked to metabolic effects, but gancaonin N itself had never been examined for its potential to modulate fat cell formation and lipid metabolism.

To close that gap, the research team deployed a two-pronged strategy. First, they used network pharmacology, a computational framework that maps the interactions between bioactive compounds, their molecular targets, and disease-associated genes. By predicting the targets of gancaonin N and intersecting them with genes linked to obesity, the team identified 17 overlapping targets. Enrichment analyses using the Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes pointed toward pathways governing lipid metabolism, adipocyte differentiation, and AMP-activated protein kinase signaling, a central energy-sensing cascade within cells.

Central to these computational predictions were two hub genes with well-documented roles in fat biology: peroxisome proliferator-activated receptor gamma, often described as the master transcriptional regulator of adipocyte differentiation, and fatty acid synthase, the enzyme responsible for de novo lipid synthesis. The network analysis suggested that gancaonin N might act on precisely the molecular machinery that drives cells toward the fat-storing phenotype, setting the stage for laboratory confirmation.

For the experimental phase, the researchers turned to 3T3-L1 preadipocytes, mouse cells that can be reliably driven to differentiate into mature adipocytes using a hormonal cocktail that includes 3-isobutyl-1-methylxanthine, dexamethasone, and insulin, a protocol abbreviated as MDI. This model is a cornerstone of adipogenesis research because it recapitulates, with remarkable fidelity, the transcriptional and morphological changes that accompany fat cell development in living tissue. When the team treated differentiating cells with gancaonin N, the results were striking.

Oil Red O staining, the classic technique that renders accumulated lipid droplets a vivid red, revealed that adipocyte differentiation and lipid accumulation were significantly inhibited in a concentration-dependent manner. In other words, the more gancaonin N the cells received, the less fat they stored. The suppression was not merely cosmetic: molecular analyses at both the protein and messenger RNA levels confirmed a coordinated shutdown of the adipogenic program.

Western blotting and PCR analyses showed downregulation of the key transcription factors that orchestrate adipocyte identity, including PPARγ, CCAAT/enhancer-binding protein alpha, and sterol regulatory element-binding protein 1c. These regulators function as a hierarchical circuit: C/EBPα and PPARγ reinforce each other’s expression to lock cells into the adipocyte fate, while SREBP-1c drives the expression of lipogenic enzymes. Their coordinated suppression indicates that gancaonin N intervenes early and broadly in the differentiation cascade rather than acting on a single downstream node.

The compound also suppressed lipogenic genes such as fatty acid synthase and fatty acid binding protein 4, or FABP4, proteins that equip mature adipocytes to synthesize and store lipid. Perhaps most intriguingly, gancaonin N was associated with activation of AMP-activated protein kinase, a cellular energy sensor that, when switched on, shifts metabolism away from synthesis and storage and toward fatty acid oxidation and energy expenditure. AMPK activation is a mechanism shared by several established metabolic interventions, including exercise and the diabetes drug metformin, which lends mechanistic plausibility to the observed anti-adipogenic effects.

The study’s integrated design deserves attention in its own right. By using network pharmacology to generate hypotheses and then validating them in a controlled cellular system, the researchers demonstrated a workflow that can efficiently triage natural compounds for metabolic activity, potentially accelerating the discovery of anti-obesity agents from the vast repository of traditional medicine. The authors emphasize that gancaonin N appears to regulate adipocyte differentiation and lipid metabolism through multiple signaling pathways simultaneously, a multi-target profile that distinguishes it from single-node approaches.

Important caveats remain. The evidence is confined to a cell culture model, and the journey from inhibited lipid droplets in a petri dish to a clinically meaningful effect on human body weight is long and uncertain, requiring studies in animal models and, eventually, controlled human trials to establish efficacy, bioavailability, and safety. Nevertheless, the identification of a licorice-derived isoflavone that converges on PPARγ, SREBP-1c, and AMPK, three of the most consequential nodes in metabolic regulation, provides a compelling molecular foundation for further exploration. As obesity rates continue to climb globally, compounds like gancaonin N illustrate how ancient pharmacopeias may still yield modern therapeutic insights when subjected to the scrutiny of contemporary molecular science.

The choice of gancaonin N as a study subject reflects a broader trend in pharmacognosy, the discipline that investigates medicines derived from natural sources. Licorice root contains hundreds of structurally diverse secondary metabolites, including glycyrrhizin, flavonoids, chalcones, and isoflavones, many of which carry prenyl side chains. Prenylation, the attachment of a hydrophobic isoprenoid group to a flavonoid scaffold, generally increases a molecule’s lipophilicity and can enhance its affinity for cellular membranes and intracellular protein targets. This structural feature may help explain why prenylated isoflavones from licorice have repeatedly attracted attention in studies of inflammation, cancer biology, and now energy metabolism, since improved membrane permeability can translate into more pronounced activity in cultured cells.

The network pharmacology approach used by the team deserves further explanation for readers unfamiliar with the method. Rather than testing a compound against one presumed target at a time, network pharmacology treats drug action as a web of interactions. Researchers first compile a list of proteins predicted to bind the compound, drawing on databases of known drug-target relationships and structural similarity. They then overlay this list with genes statistically associated with a disease, in this case obesity, and examine where the two sets intersect. The resulting overlap, here 17 shared targets, is subjected to enrichment analysis to determine which biological processes and signaling pathways are overrepresented. This systems-level view acknowledges that most chronic diseases involve dozens of interacting pathways, and that multi-target interventions may better reflect how traditional herbal medicines have historically been understood to act.

The molecular findings also fit into a well-mapped hierarchy of fat cell biology. PPARγ sits at the apex of the adipogenic transcriptional cascade, and its activity is sufficient to drive even non-fat cells toward lipid storage, which is why it has been the target of thiazolidinedione diabetes drugs. Downstream of these transcription factors, FABP4 serves as a cytoplasmic chaperone for fatty acids and is widely used as a marker of mature adipocyte function. Upstream, AMPK acts as a fuel gauge: when cellular energy levels fall, AMPK phosphorylates downstream targets such as acetyl-CoA carboxylase, thereby throttling fatty acid synthesis and promoting oxidation. The observation that gancaonin N both suppresses pro-adipogenic transcription factors and engages this energy-sensing pathway suggests a coordinated mechanism rather than a single point of interference.

The 3T3-L1 model itself has a long pedigree. Derived from mouse embryos in the 1970s, these cells have been used in thousands of studies precisely because their differentiation is robust, reproducible, and amenable to quantitative readouts such as Oil Red O extraction and spectrophotometric measurement. Findings in this system, however, do not automatically translate to human physiology. Human adipocytes differ in gene expression patterns, receptor repertoires, and metabolic flux, and the concentrations of a compound that are achievable in culture medium often far exceed what can be reached in circulating blood after oral ingestion. Absorption, metabolism by liver enzymes, and rapid excretion can all diminish the effective exposure of tissues to a dietary flavonoid.

These considerations frame the appropriate next steps. Animal studies using diet-induced obesity models would test whether gancaonin N or licorice extracts enriched in it can influence weight gain, insulin sensitivity, and adipose tissue morphology in a living organism. Pharmacokinetic profiling would establish whether meaningful plasma concentrations are attainable and whether the compound accumulates in adipose tissue. Safety evaluation is equally essential, since licorice is known to contain constituents with documented physiological effects, and any candidate derived from this plant would need to demonstrate a favorable therapeutic window.

The research was conducted by investigators affiliated with the College of Korean Medicine at Kyung Hee University in Seoul, together with collaborators at the Korea Institute of Science and Technology, and was supported by funding from the Korea Health Industry Development Institute under the Ministry of Health and Welfare of the Republic of Korea. The work was published as an open access article under a Creative Commons Attribution license, received in October 2025 and accepted in August 2026, allowing the scientific community unrestricted access to the methods and data. As with all early-stage findings, the value of this study lies less in immediate application than in the hypothesis it generates: that a defined molecule from a traditional medicinal plant can be traced, target by target, through the molecular circuitry of fat cell formation.

Subject of Research: Anti-adipogenic effects of the licorice-derived compound gancaonin N on adipocyte differentiation and lipid metabolism in 3T3-L1 cells

Article Title: Anti-adipogenic effects of gancaonin N, a bioactive compound from Glycyrrhiza uralensis, in MDI-Induced 3T3-L1 adipocytes

Article References: Kim, S. W., Kwon, S., Jee, W., Kim, N., Kim, M., Byun, D. Y., Kwon, S., Lee, H.-G., Chung, W.-S., & Jang, H.-J. (2026). Anti-adipogenic effects of gancaonin N, a bioactive compound from Glycyrrhiza uralensis, in MDI-Induced 3T3-L1 adipocytes. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05566-1

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05566-1

Keywords: gancaonin N, Glycyrrhiza uralensis, adipogenesis, obesity, lipid metabolism, AMPK signaling, PPARγ, 3T3-L1 adipocytes, network pharmacology, licorice, fatty acid synthase, natural products